In a groundbreaking discovery from Weill Cornell Medicine, researchers have revealed that activated T cells, key players in the body's defense against cancer, secrete tiny capsules known as extracellular vesicles loaded with DNA. This novel mechanism amplifies the immune system's ability to detect and destroy tumors, particularly those that are immunologically 'cold' and evade traditional detection. The study, conducted at the Sandra and Edward Meyer Cancer Center, uncovers how these vesicles transfer DNA to both immune cells and tumor cells, enhancing antigen presentation and sparking a robust anti-tumor response.

T cells, or T lymphocytes, are white blood cells central to adaptive immunity. Cytotoxic CD8+ T cells directly kill infected or cancerous cells by recognizing foreign peptides presented on major histocompatibility complex (MHC) class I molecules on target cell surfaces. Helper CD4+ T cells orchestrate broader responses by activating other immune components. However, many aggressive cancers like pancreatic ductal adenocarcinoma (PDAC), glioblastoma (GBM), and triple-negative breast cancer suppress MHC expression and antigen processing, rendering them invisible to T cells.

🧬 The Role of Extracellular Vesicles in Cellular Communication

Extracellular vesicles (EVs) are nanoscale membrane-bound particles released by cells to communicate with distant targets. Ranging from 50 to 350 nanometers, they carry proteins, lipids, RNA, and DNA. In cancer, tumor-derived EVs often suppress immunity, but this research flips the script by examining EVs from activated T cells (AT-EVs). These vesicles preferentially home to immune hubs like lymph nodes and spleen via adhesion molecules such as ICAM-1, where they are taken up by antigen-presenting cells like dendritic cells (DCs).

Unpacking the DNA Cargo in AT-EVs

AT-EVs are packed with double-stranded DNA (dsDNA), predominantly nuclear genomic DNA fragments (150 bp to 20 kb, peaking at 2 kb). Unlike random snippets, this DNA is enriched for immune-related genes, including those for MHC molecules (H2-Kb, H2-Kd), immunoproteasome subunits (Psmb8/9), and peptide transporters (Tap1/2). About 7.7% derives from newly synthesized DNA, suggesting active packaging during T cell activation with stimuli like anti-CD3/CD28 and IL-2.

Surface proteomics reveals enrichment in granzyme B (Gzmb), a serine protease typically used for target cell killing. This enzyme acts as a 'molecular drill,' disrupting the nuclear envelope of recipient cells to enable DNA entry into euchromatin regions for transient expression—lasting days without genomic integration.

Study Design: From Bench to Preclinical Models

Led by co-senior authors Dr. David Lyden, Dr. Haiying Zhang, and Dr. Irina Matei, with co-first authors Dr. Diao Liu and Dr. Mengying Hu, the team isolated AT-EVs from mouse spleen and lymph node T cells cultured ex vivo. Characterization used nanoparticle tracking analysis, electron microscopy, and sequencing. Key models included orthotopic PDAC (KPCY clones with low T cell infiltration), intracranial GBM (SB28), and orthotopic triple-negative breast cancer (PyMT-Tlo). Treatments involved intravenous or intratumoral AT-EV infusions (five doses every three days), alone or with anti-PD-1 checkpoint blockade.

• EV biodistribution tracked via near-infrared dyes.
• RNA-seq and flow cytometry assessed antigen processing and presentation (APP) changes.
• DNase treatment confirmed DNA's necessity by abolishing effects.

Reviving Antigen Presentation in Immune Cells

In dendritic cells, AT-EVs upregulated APP machinery over 10-fold, boosting MHC-I/II surface expression (e.g., CD86 maturation marker) and allogeneic T cell proliferation. This occurred independently of major cytosolic sensors like cGAS-STING (no TBK1 phosphorylation) or TLR9/AIM2, with minimal IFN-γ contribution. Instead, direct nuclear DNA transfer restored MHC in MHC-deficient cells, enabling cross-presentation of ovalbumin antigens to CD8+ T cells.

Targeting Tumors: Making the Invisible Visible

In 'cold' tumors, AT-EVs infiltrated via ICAM-1, upregulating APP genes 2-4 fold and prompting tumors to secrete their own EVs. Tumor MHC-I increased, attracting CD8+ T cells, NK cells, and DCs while reducing suppressive myeloid-derived suppressor cells (MDSCs). Tertiary lymphoid structures (TLS)—immune aggregates prognostic for better outcomes—formed prominently in treated pancreatic tumors.

Preclinical Efficacy Across Cancer Types

In GBM models, AT-EVs halted progression in 50% of mice, extending survival. For PDAC, combination therapy suppressed growth, reduced metastases, and enlarged lymph nodes with activated IFNγ+ CD8+ T cells. Breast cancer burdens dropped with enhanced infiltration. DNase-treated or granzyme B-inhibited EVs lost efficacy, proving the DNA-Gzmb axis.

A Positive Feedback Loop for Amplified Immunity

The discovery reveals a self-reinforcing cycle: Activated T cells release AT-EVs → EVs boost APP in DCs (better T priming) and tumors (increased visibility and EV production) → More activated T cells. This counters viral and cancer evasion tactics suppressing APP.

Dr. Lyden noted, “These findings reveal a natural mechanism for treating immunologically silent tumors.” Dr. Matei added, “There seems to be a positive-feedback loop... promoting their recognition by the immune system.”

Therapeutic Horizons: Acellular Immunotherapy

AT-EVs offer a cell-free alternative to CAR-T therapies, leveraging natural homing and transient gene delivery for safety. Synergy with checkpoint inhibitors could revive responses in refractory cases. As non-viral vectors, they may deliver custom genes efficiently. Translation efforts focus on human AT-EVs from peripheral blood and dosing optimization. For deeper insights, explore the full study in Cancer Cell.

Weill Cornell's Leadership in Cancer Research

This work from the Lyden lab builds on prior EV studies priming liver immunity against metastases. Weill Cornell Medicine, affiliated with Cornell University, exemplifies higher education's role in translational oncology. Such innovations drive demand for immunologists and researchers. Visit the Weill Cornell news release for more.

Future Directions and Challenges

Challenges include scaling EV production, ensuring human efficacy, and monitoring off-target effects. Future studies will probe CD4+ vs. CD8+ EV differences and combination with vaccines. Broader applications span autoimmunity and infections. Additional coverage in Genetic Engineering & Biotechnology News highlights gene therapy potential.

Implications for Immuno-Oncology Careers

Breakthroughs like this underscore opportunities in academia. Researchers skilled in EV biology, T cell engineering, and tumor immunology are in demand at institutions like Weill Cornell.

Photo by julien Tromeur on Unsplash